Emerging data suggest this peptide, a dual agonist targeting both GLP-1 and GIP , could offer a notable step forward for body loss . Initial clinical trials have shown considerable reductions in https://getretatrutideaustralia.com/blog/retatrutide-results-side-effects-cost